Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04555811
Other study ID # 2019LS230
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date September 22, 2020
Est. completion date February 2, 2024

Study information

Verified date February 2023
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.


Description:

This study uses a single dose of the investigational product FT596 in the early post-transplant period. Rituximab or an FDA approved by biosimilar including Rituxan®, Truxima®, and Ruxience™ is given 48 to 72 hours prior to FT596. The goal of this study is to 1) establish a maximum tolerated dose (MTD) of FT596 when given 30 days after transplant and 2) to confirm the MTD and safety of giving a single dose of FT596 at Day 7 post-transplant starting at one dose level below the MTD identified at Day 30.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 3
Est. completion date February 2, 2024
Est. primary completion date February 8, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of diffuse large B cell lymphoma or aggressive (high-grade) B-cell lymphoma for which an autologous stem cell transplant is planned or recently completed - High risk for relapse defined as at least one of the below: - Primary induction failure (no complete or partial remission at any point after diagnosis - Initial remission duration < 12 months - Lack of complete metabolic (PET scan) response after 2-3 cycles of salvage chemotherapy - Evidence of c-myc and bcl-2 and/or bcl-6 re-arrangement (double hit or triple hit lymphoma) - Age-adjusted IPI 2-3 at relapse - Age 18 years or older at the time of signing consent. - Agrees to use adequate contraception (or evidence of sterility) for at least 12 months after the last dose of rituximab. - Agrees and signs the separate consent for up to 15 years of follow-up (Long-term Follow-up study CPRC#2020LS052) - Provides voluntary written consent prior to the performance of any research related activities. Exclusion Criteria: - Receipt of any investigational therapy within 28 days prior to the first dose of FT596 or planned use of an investigational therapy during the first 100 days after transplant - Planned post-transplant irradiation prior to Day +100 - Seropositive for HIV, active Hepatitis B or C infection with detectable viral load by PCR - Body weight <50kg - Known allergy to the following FT596 components: albumin (human) or DMSO - Unable to receive rituximab Post-HSCT Reconfirmation of eligibility - No life-threatening medical issues (i.e. ongoing Grade 4 adverse events) where, in the opinion of the treating investigator, use of FT596 is not in the patient's best interest. - No active uncontrolled infection. - Adequate organ function post-transplant including: - alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =5 x ULN (Grade 2 CTCAE v5) - total bilirubin =1.5 x ULN (Grade 1 CTCAE v5) - serum creatinine =1.5 x ULN (Grade 1 CTCAE v5) - oxygen saturation =93% on room air - For Day 30 dosing only - CBC requirement consistent with engraftment (ANC>500, platelet>20,000 without transfusion support within previous 7 days). There are no CBC parameters for Day 7 dosing. - No requirement for systemic immunosuppressive therapy (> 5mg prednisone daily) during the FT596 dosing period.

Study Design


Intervention

Drug:
FT596
FT596 is given 2-3 days after rituximab; however, it may be delayed for up to 7 days until all rituximab infusion related toxicities resolve to =Grade 1.
Rituximab
Rituximab 375 mg/m^2 is administered as an IV infusion per institutional standard of care and package insert on 2-3 days (48 to 72 hours) prior to the FT596 infusion

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota
United States Washington University School of Medicine - Siteman Cancer Center Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants experiencing dose limiting toxicity events The component I design (FT596 on day 30) will continue until the MTD is declared or until the first dose is declared to be above MTD. The component I dose limiting toxicity (DLT) is defined as any of the following events within 28 days after the FT596 dosing based on CTCAE v5:Grade 4 hematologic toxicity lasting > 7 days ,Grade 4 non-hematologic toxicity ,Grade =3 Infusion Related Reaction, Grade 2 acute GVHD that requires steroid therapy >7 days or progression after 3 days of steroids or has partial response after 14 days of treatment, Grade =3 acute GVHD, Grade 4 cytokine release syndrome (CRS), Grade 3 CRS that does not resolve to < Grade 2 in 72 hours, Grade 3 neurotoxicity, Grade 3 organ toxicity involving vital organs, Any Grade 3 non-hematological toxicity that does not resolve to =Grade 2 within 72 hours 28 Days Post FT596 infusion
Secondary Number of participants experiencing adverse events Number of participants experiencing adverse events related to FT596 post auto-HSCT in combination with rituximab 1 year post FT596 infusion
Secondary Number of participants with relapse/progression Number of participants experiencing progression or relapse at 12 months post auto HSCT 1 year post auto HSCT
Secondary Number of non-relapse mortality incidents at 100 days post HSCT Number of participants experiencing non-relapse mortality at 100 days post auto-HSCT. 100 days post HSCT
Secondary Number of non-relapse mortality incidents at one year post HSCT Number of participants experiencing non-relapse mortality at one year post auto-HSCT. one year post auto-HSCT
See also
  Status Clinical Trial Phase
Recruiting NCT04670029 - Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line Phase 3
Active, not recruiting NCT04572763 - Copanlisib Plus Venetoclax in R/R DLBCL Phase 1/Phase 2
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Completed NCT03287817 - CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma Phase 1/Phase 2
Enrolling by invitation NCT05645744 - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Completed NCT04316624 - A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy Phase 1
Terminated NCT04189952 - Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma Phase 2
Recruiting NCT01949818 - Treatment of Diffuse Large B Cell Lymphoma Phase 4
Completed NCT01459887 - Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma Phase 3
Completed NCT03242902 - To Decrease Fatigue With Light Therapy Phase 3
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Recruiting NCT05018520 - The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk Phase 3
Withdrawn NCT04052061 - QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma Phase 1
Recruiting NCT05020392 - Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma Phase 3
Recruiting NCT05006716 - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies Phase 1/Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Not yet recruiting NCT05834426 - Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers